Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cis and trans regulatory mechanisms of extrachromosomal DNA segregation.

Nature cell biology·2026
Same author

Dose-dependent hormone actions at estrogen receptor enhancers specify distinct molecular and biological outcomes.

Science advances·2026
Same author

Accurate prediction of ecDNA in interphase cancer cells using deep neural networks.

Communications biology·2026
Same author

TWIST1 mediated transcriptional activation of SPON2 drives colorectal cancer peritoneal metastasis through stromal cell signaling network.

Oncogene·2026
Same author

Publisher Correction: PtdIns(3,5)P<sub>2</sub> is an endogenous ligand of STING in innate immune signalling.

Nature·2026
Same author

<i>Cis</i> and <i>Trans</i> Regulatory Mechanisms of ecDNA Segregation.

bioRxiv : the preprint server for biology·2026

相关实验视频

Updated: Jan 10, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

3.0K

以ecDNA驱动的瘤基因超表达剂塑造了免疫扩散性瘤微环境.

Kailiang Qiao1, Qing-Lin Yang1,2, Tuo Li2,3,4

  • 1Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.

bioRxiv : the preprint server for biology
|November 26, 2025
PubMed
概括

外染色体DNA (ecDNA) 通过创造"超表达"细胞来驱动胰腺癌的攻击和免疫逃避. 这些细胞重塑瘤微环境,减少T细胞透,促进癌症生长.

更多相关视频

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.4K

相关实验视频

Last Updated: Jan 10, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

3.0K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.4K

科学领域:

  • 在瘤学瘤学.
  • 癌症遗传学 癌症遗传学
  • 免疫学 免疫学 免疫学

背景情况:

  • 染色体外DNA (ecDNA) 有助于癌症的遗传异质.
  • 新出现的证据表明,ecDNA与免疫逃避之间存在联系,但根本机制尚未完全理解.

研究的目的:

  • 调查ecDNA在胰腺管腺癌 (PDAC) 进展和免疫逃避中的作用.
  • 阐明ecDNA影响瘤微环境 (TME) 和抗瘤免疫的机制.

主要方法:

  • 基因工程对PDAC的小鼠模型.
  • 单细胞转录和组织学分析.
  • 对TME组件的分析,包括与癌症相关的纤维细胞 (CAF) 和T细胞.

主要成果:

  • 以ecDNA驱动的瘤,其特征是放大了Kras和Myc瘤基因,在免疫能力强的小鼠中表现出增加的攻击性.
  • ecDNA促进免疫扩散性TME的快速建立,增加肌纤维细胞CAF (myCAF) 和减少T细胞透.
  • 癌细胞的一个子集,称为"超表达体",表现出极高的Kras表达,分泌安菲瑞古林,促进myCAF扩张,并抑制T细胞透.

结论:

  • ecDNA在TME重塑中起着因果作用,有助于胰腺癌异质性和免疫逃避.
  • 由ecDNA驱动的超表达细胞在PDAC中建立了一个免疫扩散的利基.
  • 准ecDNA或其下游效应因子可能代表PDAC的新治疗策略.